Latest Breaking News On - Norwegian regional health authorities - Page 1 : comparemela.com

May 5, 2021 Therapeutic drug monitoring, half-dosing may not be ready for prime-time Therapeutic drug monitoring (TDM) for patients with immune-mediated inflammatory diseases did not lead to better clinical remission rates, while routine dose reduction of anti-rheumatic drugs for patients with rheumatoid arthritis (RA) in remission offered modest benefits, according to two Norwegian trials. In the NOR-DRUM Part A trial, clinical remission at week 30 was achieved in 50.5% of 198 patients with TDM versus 53% of 200 patients in the standard therapy group, for an adjusted difference of 1.5% (95% CI −8.2% to 11.1%, P=0.78), reported Silje Watterdal Syversen, MD, PhD, of Diakonhjemmet Hospital in Oslo, and co-authors. In the ARCTIC REWIND trial, disease flare occurred in 25% of 77 patients in the half-dose conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) group versus 6% in the stable-dose csDMARD group for a risk difference of 18% (95% CI 7%-29%), reported Si

Silje watterdal syversenNovartis norgeDaiichi sankyoEli lillyInfliximab remicadeSiri lillegravenShalmali palOrion pharmaJeffreyr curtisNorwegian regional health authoritiesBoehringer ingelheimThermo fisherUniversity of alabama at birminghamSouth eastern norway regional health authoritySouth eastern norway regional health authoritiesResearch council of norway